MAPT and Alzheimer disease: In addition, Koppel et al. (2016) reported that a tau mouse model of AD treated with DA2R antagonist haloperidol showed a significant reduction in tau phosphorylation associated with an inactivation of the tau kinase AMPK, whereas a study by Ziu et al. (2020) suggested an effective role of DA2/3R agonists in inhibiting tau aggregation.